uniQure NV (QURE US)

Analysis

Health Care • Netherlands

uniQure N.V. delivers gene therapy with single treatments for curative results. The Company develops a modular platform to bring new disease modifying therapies to patients with severe genetic diseases, as well as offers ongoing clinical programs in hemophilia B and pre-clinical proof-of-concept in Huntington's disease.

Refresh

Company Presentation • 29 Sep 2026 20:30

Study update

Company Presentation • 13 Jan 2026 20:00

Corporate presentation

Company Presentation • 24 Sep 2025 20:30

Study Result

Company Presentation • 09 Jan 2025 20:00

Corporate Presentation

Company Presentation • 09 Dec 2020 06:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Study update

Corporate presentation

Study Result

Corporate Presentation

Study Update